New Insights into Oropharyngeal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (15 October 2022) | Viewed by 4924
Special Issue Editors
Interests: head and neck cancer; cell cycle; drug resistance; stemness; EMT; surgery; chemoradiotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Oropharyngeal cancer has recently attracted the attention of more researchers in the field of head and neck malignancy. Particularly, HPV-associated oropharyngeal squamous cell carcinoma (SCC), which is increasingly common in economically developed countries, shows high sensitivity to chemoradiation. It is clearly biologically different from conventional smoking-related and drinking-related oropharyngeal SCC. Immunostaining of p16 as a marker for HPV-associated oropharyngeal SCC has been adopted in the 8th edition of the UICC stage classification. As a result, clinical studies are underway in many countries to reduce the intensity of chemoradiation therapy for HPV-associated oropharyngeal SCC. Although it has already been demonstrated that some subgroups of HPV-associated oropharyngeal SCC have poor prognosis, appropriate treatment for these subgroups has not yet been determined. Additionally, many scientific issues remain to be clarified, such as the biological mechanisms of the tumor microenvironment, including immuno-oncology. Novel findings obtained from clinical study are expected to be crucially important for indications of surgery or chemoradiotherapy for both HPV-related and HPV-unrelated oropharyngeal cancer. Consequently, it is necessary to accumulate new knowledge related to unresolved oropharyngeal cancer. The reports presented in this Special Issue are expected to enhance our understanding of the biological characteristics of oropharyngeal SCC and to promote future clinical applications and breakthroughs.
Dr. Narita Norihiko
Dr. Hideki Matsumoto
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oropharyngeal squamous cell carcinoma
- HPV
- chemoradiation therapy
- surgery
- clinical trial
- immuno-oncology
- molecular biological research
- translational research
- recurrence and metastasis
- drug resistance
